Renaissance Technologies LLC lessened its holdings in Repligen Corporation (NASDAQ:RGEN) by 52.4% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 299,400 shares of the biotechnology company’s stock after selling 329,000 shares during the quarter. Renaissance Technologies LLC owned approximately 0.88% of Repligen Corporation worth $12,407,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of RGEN. Karp Capital Management Corp purchased a new stake in shares of Repligen Corporation during the 1st quarter worth $506,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Repligen Corporation during the 1st quarter worth $103,000. Mason Street Advisors LLC raised its stake in Repligen Corporation by 7.0% in the first quarter. Mason Street Advisors LLC now owns 7,914 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 521 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Repligen Corporation by 10.9% in the first quarter. Envestnet Asset Management Inc. now owns 7,082 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 694 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares during the last quarter. 96.45% of the stock is currently owned by institutional investors and hedge funds.
Repligen Corporation (NASDAQ:RGEN) opened at 38.12 on Friday. The stock has a market cap of $1.42 billion, a P/E ratio of 74.60 and a beta of 1.18. The company’s 50-day moving average price is $40.03 and its 200-day moving average price is $39.88. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81.
Repligen Corporation (NASDAQ:RGEN) last released its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The business’s revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.16 EPS. Equities analysts forecast that Repligen Corporation will post $0.59 earnings per share for the current year.
WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/28/renaissance-technologies-llc-trims-position-in-repligen-corporation-rgen.html.
RGEN has been the topic of several analyst reports. BidaskClub raised Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Thursday, October 5th. William Blair initiated coverage on Repligen Corporation in a report on Friday, July 21st. They issued an “outperform” rating on the stock. TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Finally, Stephens restated an “overweight” rating and issued a $50.00 target price on shares of Repligen Corporation in a research report on Tuesday, September 26th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Repligen Corporation currently has a consensus rating of “Buy” and an average price target of $45.40.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.